Hypertension Management in Coronary Artery Disease Patients

First-Line Medication Regimen

The American College of Cardiology recommends starting with a β-blocker, especially if prior MI, adding an ACE inhibitor or ARB, and including a thiazide or thiazide-like diuretic as foundational therapy for hypertensive patients with CAD 1, 2, 3
The American Heart Association suggests that β-blockers are mandatory in patients with prior MI and strongly recommended for all CAD patients with hypertension 1, 2, 3
Preferred β-blocker agents include carvedilol, metoprolol succinate, metoprolol tartrate, nadolol, bisoprolol, propranolol, or timolol, while atenolol should be avoided due to its inferior outcomes compared to other β-blockers 3
ACE inhibitors or ARBs are recommended with a Class I indication, particularly in patients with prior MI, LV systolic dysfunction, diabetes mellitus, or CKD 1, 2, 4, 3
Thiazide or thiazide-like diuretics are essential for blood pressure control, with chlorthalidone being the preferred thiazide-like agent 1, 2, 4, 6

The American College of Cardiology recommends adding a long-acting dihydropyridine CCB, such as amlodipine, to the basic triple regimen if angina or hypertension remains uncontrolled, with a Class IIa recommendation and Level of Evidence B 1, 2, 7, 3
If β-blockers are contraindicated or cause intolerable side effects, substituting with a nondihydropyridine CCB, such as diltiazem or verapamil, is recommended, but nondihydropyridine CCBs should not be used if LV dysfunction is present 1, 2, 4, 6, 5

The American Heart Association recommends a standard blood pressure target of <140/90 mm Hg for patients with stable angina, with a Class I indication and Level of Evidence A 1, 2, 4, 7, 6
A lower target of <130/80 mm Hg may be considered in select individuals with previous stroke or transient ischemic attack, CAD risk equivalents, or prior MI, with a Class IIb recommendation and Level of Evidence B 1, 2, 4, 7, 3
Diastolic blood pressure should not be lowered below 60 mm Hg, especially in patients with myocardial ischemia, and systolic blood pressure should not be lowered below 130 mm Hg in octogenarians 5

The American College of Cardiology recommends continuing β-blockers beyond 3 years as long-term therapy for hypertension in post-MI patients, with a Class IIa recommendation 3
In patients with heart failure and reduced ejection fraction, adding aldosterone receptor antagonists, such as spironolactone or eplerenone, is recommended if NYHA class II-IV with ejection fraction <40%, but nondihydropyridine CCBs should be avoided due to Class III Harm 9, 5
In acute coronary syndromes, lowering blood pressure without delay is recommended to reduce hemorrhagic stroke risk in patients with uncontrolled severe hypertension taking antiplatelet or anticoagulant drugs 1, 2, 4, 7

Atenolol should not be used due to its inferior outcomes compared to other β-blockers 3
Combining β-blockers with nondihydropyridine CCBs should be avoided unless absolutely necessary due to bradyarrhythmia risk 1, 2, 7
Nondihydropyridine CCBs should not be used in LV dysfunction due to Class III Harm 1, 2, 5
Diastolic blood pressure should not be lowered below 60 mm Hg due to the risk of worsening myocardial ischemia 5

Long-acting nitrates can be added for angina relief when β-blockers alone are insufficient, but nitrates are not effective for hypertension management per se 1, 7, 6
Antiplatelet drugs and lipid-lowering agents have no special contraindications in hypertensive CAD patients 1, 4, 7